Abstract
We describe the pharmacokinetic profile of mycophenolic acid (MPA) in a patient receiving Mycophenolate mofetil (MMF) during her first and second renal transplantations. The MMF dose required to achieve a therapeutic range of MPA-AUC 0-12 h early following the second transplantation was 10 times greater than that required late following the first transplantation. Her MMF requirement then declined and continued to decrease even beyond 1 year. Intra-individual variability in MPA profiles precluded the ability to predict MMF dosing for the second transplant based on that during the first. Therapeutic drug monitoring of MMF should be continued beyond 1 year of transplantation.
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Background
Mycophenolate mofetil (MMF), which is widely prescribed in renal transplantation, is rapidly absorbed and converted to its active moiety, mycophenolic acid (MPA). Therapeutic drug monitoring (TDM) of MPA is advocated because of large inter-individual variability in pharmacokinetic profiles [1] . Individualization of MMF dose based on the maintenance of MPA area under the curve (MPA-AUC 0-12h ) within 30-60 mg h/L reduces renal allograft rejection [2] .
Case report
A 34-year-old woman, who had lost her native kidney function to lupus nephritis, received her first renal allograft from her haplo-matched mother in July, 1994. She received cyclosporine, azathioprine and prednisolone without an induction agent. Her nadir serum creatinine was 1.5 mg/dL. After 1 year following transplantation, cyclosporine was withdrawn according to protocol and it was not re-introduced. Two years later, a worsening of graft function (serum creatinine of 2.5 mg/dL) and leucopoenia prompted a switch from azathioprine to MMF (CellCept ® , Roche Ltd, Basel, Switzerland). In 2003, TDM of MPA became available in our centre. Six years after starting MMF, when her serum creatinine was stable at 2.5 mg/dL, her first full MPA-AUC 0-12h was 132.5 mg h/L during a total MMF dose of 2000 mg/D. She was evaluated as a regular patient and not as a special study patient. Hence, all subsequent measurements for MPA-AUC were calculated by limited sampling strategies derived from patients receiving cyclosporine as co-therapy [3] , which is accepted as valid when applied to patients co-treated with tacrolimus (unpublished observations from Mathew et al. Table 1 . Her graft function continued to worsen rapidly, she was started on renal replacement therapy, and MMF was discontinued in July, 2007.
In (Table 1 ). In the subsequent weeks, a careful tapering of the MMF dose was required because of high DC-AUC and recurrent urinary tract infections. During the subsequent period of MPA-AUC 0-12h measurement, serum albumin levels were normal. The co-medications were not known to interfere with the MPA pharmacokinetics or with the MPA assay. The tacrolimus dose started after the second transplantation was 5.5 mg/D (target tacrolimus trough concentration (C 0 ) = 7-12 ng/mL, actual C 0 = 15.1 ng/mL), and it was reduced gradually over a year to 1 mg/D (target C 0 = 3-5 ng/mL, actual C 0 = 3.1 ng/mL). Serum creatinine levels, MMF dose and corresponding MPA-AUC 0-12h are shown in Figure 1 .
Discussion
At 8 years following her first transplantation (while off cyclosporine), during a decline in renal function, our patient required a MMF dose of~9 mg/kg/D to maintain the therapeutic target MPA-AUC 0-12h . The MPA-AUC 0-12h immediately after transplantation may be lower than during the stable post-transplant period [5] . After the second renal transplantation, the patient received tacrolimus, which does not significantly affect MPA concentrations or AUC [6] . However, in our patient, an increase in MMF dose up to 5000 mg/D (~90 mg/kg/D, i.e. 10 times the dose required during the later period of the first transplant) was required to obtain MPA concentrations in the therapeutic range. MPA exposure is critical in second transplants, in pre-sensitized recipients and in tacrolimus minimization regimes. Administration of the same MMF dose given late during the first post-transplant period would have resulted in very low MPA-AUC 0-12 h , predisposing to early rejection. In renal transplant patients, there may be up to 10-fold inter-individual variability in the pharmacokinetic profile of MPA. The absorption profile of MPA can be affected by food, drugs such as antacids [7] and alterations in enterohepatic circulation (cyclosporine) [6, 8] . In our patient, immediately after the second transplantation, factors such as hypoalbuminaemia (2.4 mg/dL) [9] , impaired absorption (probably due to uraemia) [10] and higher doses of prednisolone (20 mg/D) [11] may have been responsible for reducing total MPA-AUC 0-12h . Over time, the MMF dose required to achieve the target MPA-AUC 0-12h had declined by more than half at 7 months and almost by 10 times at 18 months (~9.5 mg/kg/D). Although improvements in MPA-AUC 0-12h (exposure) at up to 6 months after transplantation have been reported [5] , we observed a steady improvement in exposure for an extended period lasting up to 15 months after the second transplantation. If TDM had been discontinued at 6 months, the patient would have received in the following months MMF doses that produce toxic MPA levels.
Conclusion
This present case demonstrated that MMF doses used immediately after the second renal transplantation cannot be predicted based on the previous MMF dose required during stable or worsening function of the first renal allograft. The intra-individual variability in MPA exposure more than a year after the second transplantation confirmed the importance of continued TDM of MPA during the stable posttransplantation period.
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